326030 — SK Biopharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00- KR₩8tn
- KR₩8tn
- KR₩548bn
Annual income statement for SK Biopharmaceuticals Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 25,999 | 418,645 | 246,179 | 354,892 | 547,596 |
| Cost of Revenue | |||||
| Gross Profit | 24,025 | 396,309 | 208,411 | 320,809 | 504,495 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 265,498 | 274,417 | 372,940 | 387,106 | 451,257 |
| Operating Profit | -239,499 | 144,227 | -126,761 | -32,214 | 96,340 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -239,909 | 71,277 | -142,469 | -43,858 | 72,596 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -247,414 | 64,846 | -139,431 | -35,379 | 226,973 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -247,414 | 64,846 | -139,431 | -32,883 | 240,738 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -247,414 | 64,846 | -139,431 | -32,883 | 240,738 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3,448 | 256 | -1,816 | -464 | 3,073 |
| Dividends per Share |